Cargando…
PPAR𝛾 Gene and Atherosclerosis: Genetic Polymorphisms, Epigenetics and Therapeutic Implications
Atherosclerosis is the leading cause of mortality and morbidity in the developed world. It is characterized by the formation of a plaque in the walls of middle and large arteries leading to macrovascular complications. Several risk factors are included, with diabetes being one of the most important...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sciendo
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231320/ https://www.ncbi.nlm.nih.gov/pubmed/30425909 http://dx.doi.org/10.2478/bjmg-2018-0011 |
_version_ | 1783370198827401216 |
---|---|
author | Grbić, E Peterlin, A Kunej, T Petrovič, D |
author_facet | Grbić, E Peterlin, A Kunej, T Petrovič, D |
author_sort | Grbić, E |
collection | PubMed |
description | Atherosclerosis is the leading cause of mortality and morbidity in the developed world. It is characterized by the formation of a plaque in the walls of middle and large arteries leading to macrovascular complications. Several risk factors are included, with diabetes being one of the most important for the onset and development of atherosclerosis. Due to an increase in the prevalence of diabetes in the world, the incidence of diabetic complications (microvascular and macrovascular) is increasing. Peroxisome proliferator-activated receptor γ (PPARγ) plays a important role in atherosclerotic processes. Peroxisome proliferator activated receptor γ belongs to the superfamily of nuclear receptors, has a great presence in fat tissue, macrophages, and regulates gene expression and most of the processes that lead to the onset and development of atherosclerosis. In this review, we discuss the basic patho-physiological mechanisms of atherosclerosis in type 2 diabetes mellitus (T2DM). Furthermore, we discuss the impact of PPARγ polymorphisms, and the epigenetic mechanisms affecting the onset of atherosclerosis, i.e, DNA methylation and demethylation, histone acetylation and deacetylation, and RNA-based mechanisms. Moreover, we add therapeutic possibilities for acting on epigenetic mechanisms in order to prevent the onset and progression of atherosclerosis. |
format | Online Article Text |
id | pubmed-6231320 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Sciendo |
record_format | MEDLINE/PubMed |
spelling | pubmed-62313202018-11-13 PPAR𝛾 Gene and Atherosclerosis: Genetic Polymorphisms, Epigenetics and Therapeutic Implications Grbić, E Peterlin, A Kunej, T Petrovič, D Balkan J Med Genet Original Article Atherosclerosis is the leading cause of mortality and morbidity in the developed world. It is characterized by the formation of a plaque in the walls of middle and large arteries leading to macrovascular complications. Several risk factors are included, with diabetes being one of the most important for the onset and development of atherosclerosis. Due to an increase in the prevalence of diabetes in the world, the incidence of diabetic complications (microvascular and macrovascular) is increasing. Peroxisome proliferator-activated receptor γ (PPARγ) plays a important role in atherosclerotic processes. Peroxisome proliferator activated receptor γ belongs to the superfamily of nuclear receptors, has a great presence in fat tissue, macrophages, and regulates gene expression and most of the processes that lead to the onset and development of atherosclerosis. In this review, we discuss the basic patho-physiological mechanisms of atherosclerosis in type 2 diabetes mellitus (T2DM). Furthermore, we discuss the impact of PPARγ polymorphisms, and the epigenetic mechanisms affecting the onset of atherosclerosis, i.e, DNA methylation and demethylation, histone acetylation and deacetylation, and RNA-based mechanisms. Moreover, we add therapeutic possibilities for acting on epigenetic mechanisms in order to prevent the onset and progression of atherosclerosis. Sciendo 2018-10-29 /pmc/articles/PMC6231320/ /pubmed/30425909 http://dx.doi.org/10.2478/bjmg-2018-0011 Text en © 2018 Grbić E, Peterlin A, Kunej T, Petrovič D, published by Sciendo http://creativecommons.org/licenses/by-nc-nd/3.0 This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. |
spellingShingle | Original Article Grbić, E Peterlin, A Kunej, T Petrovič, D PPAR𝛾 Gene and Atherosclerosis: Genetic Polymorphisms, Epigenetics and Therapeutic Implications |
title | PPAR𝛾 Gene and Atherosclerosis: Genetic Polymorphisms, Epigenetics and Therapeutic Implications |
title_full | PPAR𝛾 Gene and Atherosclerosis: Genetic Polymorphisms, Epigenetics and Therapeutic Implications |
title_fullStr | PPAR𝛾 Gene and Atherosclerosis: Genetic Polymorphisms, Epigenetics and Therapeutic Implications |
title_full_unstemmed | PPAR𝛾 Gene and Atherosclerosis: Genetic Polymorphisms, Epigenetics and Therapeutic Implications |
title_short | PPAR𝛾 Gene and Atherosclerosis: Genetic Polymorphisms, Epigenetics and Therapeutic Implications |
title_sort | ppar𝛾 gene and atherosclerosis: genetic polymorphisms, epigenetics and therapeutic implications |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231320/ https://www.ncbi.nlm.nih.gov/pubmed/30425909 http://dx.doi.org/10.2478/bjmg-2018-0011 |
work_keys_str_mv | AT grbice pparγgeneandatherosclerosisgeneticpolymorphismsepigeneticsandtherapeuticimplications AT peterlina pparγgeneandatherosclerosisgeneticpolymorphismsepigeneticsandtherapeuticimplications AT kunejt pparγgeneandatherosclerosisgeneticpolymorphismsepigeneticsandtherapeuticimplications AT petrovicd pparγgeneandatherosclerosisgeneticpolymorphismsepigeneticsandtherapeuticimplications |